BioCentury
ARTICLE | Company News

Isis Pharmaceuticals, Bayer deal

May 11, 2015 7:00 AM UTC

Isis granted Bayer exclusive, worldwide rights to develop and commercialize ISIS-FXIRx to prevent thrombosis. Bayer plans to evaluate the Factor XI antisense inhibitor in patients who are unable to ...